Long-Term Prognostic Significance of Ventricular Repolarization Dispersion in Patients with Cardiac Sarcoidosis

Kobayashi, Yuta; Nagai, Toshiyuki; Takenaka, Sakae; Kato, Yoshiya; Komoriyama, Hirokazu; Nagano, Nobutaka; Kamiya, Kiwamu; Konishi, Takao; Sato, Takuma; Omote, Kazunori; Tsujinaga, Shingo; Iwano, Hiroyuki; Kusano, Kengo; Yasuda, Satoshi; Ogawa, Hisao; Ishibashi‐Ueda, Hatsue; Anzai, Toshihisa

doi:10.1016/j.amjcard.2021.04.039

Cited by 6 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the optimal cut-off point of Tp-e may be lower in patients with some disease status. Kobayashi et al recently reported that a higher Tp-e/QT ratio predicts long-term prognosis in CS patients, and that the mean Tp-e in patients with a low Tp-e/QT ratio was 92 ms. 9 In addition, the optimal cut-off of Tp-e has been reported to be 96 ms for Brugada syndrome patients and 110 ms for heart failure patients, 7 but longer than 110 ms for the general population. 23 The optimal cut-off of Tp-e at 91 ms in the present study may be slightly lower but acceptable.…”

Section: Discussionmentioning

confidence: 99%

“…6-8, 23 More recently, Tp-e, as well as the Tp-e/QT ratio, have been reported as independent predictors for long-term prognosis in patients with CS. 9 Tp-e has been thought to reflect TDR; 3 however, it has been reported that Tp-e can be a marker for not only TDR, but also DOR in the whole ventricle. 24 In translational experimental models, the prolonged Tp-e was correlated with increased DOR in the whole ventricle enhanced by sympathetic nerve excitation.…”

Section: Discussionmentioning

confidence: 99%

“…[6][7][8] Tp-e may also be a marker of SCD in patients with CS. 9 Accordingly, the aims of this study were to: (1) clarify the characteristics of VA episodes and evaluate the incidence and efficacy of ICD therapy; and (2) investigate whether Tp-e was associated with VA events in patients with CS and ICD/CRT-D.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prolonged T-peak to T-end Interval Predicts Implantable Cardioverter Defibrillator Therapy in Patients With Cardiac Sarcoidosis

Kataoka

Daigo

Yazaki

et al. 2023

Circ J

View full text Add to dashboard Cite

Background:The association between the T-peak to T-end interval (Tp-e) and ventricular arrhythmia (VA) events in cardiac sarcoidosis (CS) is unknown. The purpose of this study was to investigate whether Tp-e was associated with VA events in CS patients with implantable cardioverter defibrillators (ICDs) or cardiac resynchronization therapy defibrillators (CRT-Ds). Methods and Results:We retrospectively studied 50 patients (16 men; mean [±SD] age 56.3±10.5 years) with CS and ICD/CRT-D. The maximum Tp-e in the precordial leads recorded by a 12-lead electrocardiogram after ICD/CRT-D implantation was evaluated. The clinical endpoint was defined as appropriate ICD therapy. During a median follow-up period of 85.0 months, 22 patients underwent appropriate therapy and 10 patients died. Kaplan-Meier analysis revealed that the probability of the clinical endpoint was 28.3% at 2 years and 35.3% at 4 years. The optimal cut-off value of the Tp-e for the prediction of the clinical endpoint was 91 ms, with a sensitivity of 72.7% and a specificity of 87.0% (area under the curve=0.81). Multivariate Cox regression analysis showed that Tp-e ≥91 ms (hazard ratio [HR] 5.10; 95% confidence interval [CI] 1.99-13.1; P<0.001) and a histological diagnosis of CS (HR 3.84; 95% CI 1.28-11.5; P=0.016) were significantly associated with the clinical endpoint. Conclusions:Tp-e ≥91 ms was a significant predictor of VA events in patients with CS and ICD/CRT-D.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prolonged T-peak to T-end Interval Predicts Implantable Cardioverter Defibrillator Therapy in Patients With Cardiac Sarcoidosis

Kataoka

Daigo

Yazaki

et al. 2023

Circ J

View full text Add to dashboard Cite

show abstract

“…1 Recent studies have shown that patients with CS have an increased risk of sudden cardiac death (SCD), which accounts for most lethal ventricular arrhythmias. [1][2][3] With new modalities, relevant prognostic information from techniques such as 18 F-fluorodeoxyglucose ( 18 F-FDG)-positron emission tomography (PET), cardiac magnetic resonance imaging and programmed electrical stimulation has been reported as useful in predicting fatal arrhythmias in CS. [4][5][6][7][8] 8-hydroxy-2′-deoxyguanosine (8-OHdG), an oxidative stress marker, is produced by oxidation of 2′-deoxyguanosine, a DNA base, under cellular oxidative stress conditions.…”

Section: Introductionmentioning

confidence: 99%

“…Cardiac sarcoidosis (CS) presents with a poor prognosis and is often associated with heart failure (HF), high-degree atrioventricular block and ventricular arrhythmia 1. Recent studies have shown that patients with CS have an increased risk of sudden cardiac death (SCD), which accounts for most lethal ventricular arrhythmias 1–3. With new modalities, relevant prognostic information from techniques such as 18 F-fluorodeoxyglucose ( 18 F-FDG)-positron emission tomography (PET), cardiac magnetic resonance imaging and programmed electrical stimulation has been reported as useful in predicting fatal arrhythmias in CS 4–8…”

Section: Introductionmentioning

confidence: 99%

Enhanced oxidative stress and presence of ventricular aneurysm for risk prediction in cardiac sarcoidosis

Yoshitomi

Kobayashi

Yano

et al. 2022

Heart

View full text Add to dashboard Cite

ObjectiveSudden cardiac death (SCD) is the major cause of death in cardiac sarcoidosis (CS). We aimed to identify the prognostic markers for sustained ventricular tachycardia (sVT) and SCD in patients with CS.MethodsWe performed a prospective observational cohort study for patients with CS diagnosed according to the Japanese or Heart Rhythm Society guidelines between June 2008 and March 2020 in our hospital. The primary endpoint was a composite of the first sVT and SCD. The levels of urinary 8-hydroxy-2′-deoxyguanosine (U-8-OHdG), a marker of oxidative DNA damage that reflects the inflammatory activity of CS, other biomarkers, and indices of cardiac function and renal function were measured on admission.ResultsEighty-nine consecutive patients with CS were enrolled; 28 patients with no abnormal 18F-fluorodeoxyglucose (18F-FDG) accumulation in the heart were excluded and 61 patients with abnormal 18F-FDG accumulation were followed up for a median of 46 months (IQR: 20–84). During the follow-up period, 15 of 61 patients showed sVT (n=12) or SCD (n=3). A Cox proportional hazard model showed that U-8-OHdG concentration and presence of ventricular aneurysm (VA) were independent predictors of first sVT/SCD. The cut-off U-8-OHdG concentration for predicting first sVT/SCD was 14.9 ng/mg·Cr. Patients with U-8-OHdG concentration ≥14.9 ng/mg·Cr and VA showed a significantly increased risk of sVT/SCD.ConclusionsU-8-OHdG and presence of VA were powerful predictors of first sVT/SCD in patients with CS, facilitating the stratification of cardiac events and providing relevant information about the substrates of ventricular tachycardia.

show abstract

A Comprehensive Review on the Electrocardiographic Manifestations of Cardiac Sarcoidosis: Patterns and Prognosis

Jain,

Marsool Marsool,

Verma

et al. 2024

Curr Cardiol Rep

View full text Add to dashboard Cite

Long-Term Prognostic Significance of Ventricular Repolarization Dispersion in Patients with Cardiac Sarcoidosis

Cited by 6 publications

References 21 publications

Prolonged T-peak to T-end Interval Predicts Implantable Cardioverter Defibrillator Therapy in Patients With Cardiac Sarcoidosis

Prolonged T-peak to T-end Interval Predicts Implantable Cardioverter Defibrillator Therapy in Patients With Cardiac Sarcoidosis

Enhanced oxidative stress and presence of ventricular aneurysm for risk prediction in cardiac sarcoidosis

A Comprehensive Review on the Electrocardiographic Manifestations of Cardiac Sarcoidosis: Patterns and Prognosis

Contact Info

Product

Resources

About